HSBC Analysts Give GlaxoSmithKline (LON:GSK) a GBX 2,110 Price Target

Share on StockTwits

GlaxoSmithKline (LON:GSK) has been assigned a GBX 2,110 ($27.76) target price by analysts at HSBC in a research note issued to investors on Wednesday, Borsen Zeitung reports. The firm currently has a “buy” rating on the stock. HSBC’s price objective would indicate a potential upside of 16.22% from the stock’s previous close.

Several other research firms have also weighed in on GSK. Jefferies Financial Group upped their price objective on shares of GlaxoSmithKline from GBX 1,850 ($24.34) to GBX 2,000 ($26.31) and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. set a GBX 1,700 ($22.36) target price on shares of GlaxoSmithKline and gave the company a “neutral” rating in a research note on Tuesday. Liberum Capital reissued a “hold” rating on shares of GlaxoSmithKline in a research note on Friday, November 15th. Credit Suisse Group boosted their price target on shares of GlaxoSmithKline from GBX 1,700 ($22.36) to GBX 1,800 ($23.68) and gave the company a “neutral” rating in a report on Thursday, October 31st. Finally, UBS Group reaffirmed a “buy” rating and issued a GBX 1,900 ($24.99) price target on shares of GlaxoSmithKline in a research note on Monday, December 2nd. One research analyst has rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 1,811.93 ($23.83).

GSK stock opened at GBX 1,815.60 ($23.88) on Wednesday. The company has a debt-to-equity ratio of 183.00, a quick ratio of 0.50 and a current ratio of 0.82. The stock has a market cap of $90.13 billion and a P/E ratio of 19.89. The firm has a 50 day simple moving average of GBX 1,736 and a 200 day simple moving average of GBX 1,671.56. GlaxoSmithKline has a 52 week low of GBX 1,429.80 ($18.81) and a 52 week high of GBX 1,796.40 ($23.63).

In other news, insider Vivienne Cox purchased 308 shares of the firm’s stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of GBX 1,725 ($22.69) per share, for a total transaction of £5,313 ($6,988.95). Over the last ninety days, insiders have purchased 330 shares of company stock valued at $569,340.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Article: What does RSI mean?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

UTG  Upgraded to Hold by ValuEngine
UTG Upgraded to Hold by ValuEngine
Simplicity Esports and Gaming  Rating Increased to Buy at ValuEngine
Simplicity Esports and Gaming Rating Increased to Buy at ValuEngine
BidaskClub Downgrades Sarepta Therapeutics  to Sell
BidaskClub Downgrades Sarepta Therapeutics to Sell
Tiptree  Lowered to Sell at BidaskClub
Tiptree Lowered to Sell at BidaskClub
Umpqua  Lowered to Hold at BidaskClub
Umpqua Lowered to Hold at BidaskClub
Varonis Systems  Downgraded by BidaskClub
Varonis Systems Downgraded by BidaskClub


© 2006-2020 Ticker Report